The market opportunities for SLE and LN lie in developing targeted therapies, guided by an understanding of epidemiological trends across major markets. Focus on age, sex, and severity can enhance ...
It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...
In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...
Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...
Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...
The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...
Flow Space on MSN
The silent burden of lupus flares: How to advocate for yourself when symptoms don't add up
Lupus is often marked by flares, which is when symptoms are usually more obvious.
People with lupus often need to use medicines to manage their symptoms. Although there are many oral medicines that treat lupus, some people with more severe symptoms may not get enough benefit from ...
Leukemia and lupus are both conditions that affect the immune system. Although they are different, they share certain symptoms. A person with lupus may have increased risk of developing leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback